PRIVILEGED & CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION ATTORNEY WORK PRODUCT TAX PRACTITIONER PRIVILEGE — IRC § 7525
This memorandum is a confidential attorney-client communication and attorney work product prepared by Calderwood & Harkness LLP. It is protected from disclosure by the attorney-client privilege, the work product doctrine, and the tax practitioner privilege under Section 7525 of the Internal Revenue Code. This memorandum is intended solely for the use of the addressees and other persons authorized by them to receive it. Any unauthorized review, use, disclosure, or distribution is strictly prohibited. If you have received this communication in error, please notify the sender immediately and destroy all copies.
CALDERWOOD & HARKNESS LLP 7 Times Square New York, New York 10036
Matter No.: 1001-00004
MEMORANDUM
TO: James Prentice, Partner (Responsible Partner, M&A) Sandra Tung, Partner (Billing Partner, M&A)
FROM: Sylvia Hartwell, Partner (Tax)
DATE: April 14, 2025
RE: Proposed Post-Closing Restructuring of Intercompany IP Licensing Arrangements Between Luminex Systems AG and Luminex Systems Inc. — Transfer Pricing Analysis
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
A. Purpose of Memorandum
This memorandum sets forth our analysis of the proposed post-closing restructuring of the existing intercompany intellectual property licensing arrangement between Luminex Systems AG ("Luminex AG"), a Swiss Aktiengesellschaft organized under the laws of Switzerland with its registered offices at Bahnhofstrasse 71, 8001 Zürich, Switzerland (Commercial Register No. CHE-284.391.057), and Luminex Systems Inc. ("Luminex US"), a Delaware corporation with its principal offices at 2100 Reston Gateway Drive, Suite 800, Reston, Virginia 20191 (EIN: 86-2547210). Luminex US is a wholly owned operating subsidiary of Luminex Systems Holdings Inc. ("Luminex Holdings"), a Delaware corporation (EIN: 86-2547193), which serves as the U.S. intermediate holding company in the Luminex corporate structure.
This memorandum has been prepared at the request of the M&A deal team at Calderwood & Harkness LLP in connection with the pending acquisition of Luminex Holdings by Ardent Capital Partners III LP ("Ardent Capital" or the "Sponsor") through Ardent Apex Holdings Inc. ("Apex Holdings"), a newly formed Delaware corporation (EIN: 93-2178435), which will serve as the post-closing parent holding company of the combined group. The analysis contained herein addresses the U.S. federal income tax, Swiss federal and cantonal tax, and OECD transfer pricing implications of the proposed intercompany licensing restructuring, and provides recommendations for implementation.
B. Current Arrangement
Under the existing intercompany intellectual property license agreement (the "Existing License Agreement"), entered into in connection with the 2021 corporate reorganization, Luminex AG licenses the "Luminex One" platform intellectual property — encompassing the company's cloud-based enterprise resource planning (ERP), procurement automation, and supply-chain analytics software-as-a-service (SaaS) platform — to Luminex US. In consideration for the license, Luminex US pays Luminex AG a royalty equal to 4.5% of Luminex US's net revenues (defined as U.S.-source revenues net of returns and allowances). Based on Luminex US's 2024 net revenues of approximately $194,800,000, the 2024 royalty payment to Luminex AG was approximately $8,766,000.
C. Proposed Restructuring
The proposed restructuring contemplates an increase in the intercompany royalty rate from 4.5% to 6.0% of Luminex US net revenues, effective as of the closing of the reverse triangular merger (the "Closing") or the first day of the post-closing fiscal period. The restructuring is intended to (i) align the royalty rate with arm's-length benchmarks as determined by Pendleton & Associates LLP's transfer pricing benchmark study (the "Benchmark Study"), and (ii) optimize the global effective tax rate of the combined post-acquisition group under Apex Holdings.
D. Key Financial Data Points
The following financial data points frame the analysis:
• Luminex 2024 Total Revenue: $487,000,000 (comprising annual recurring revenue ("ARR") of $441,000,000 and professional services revenue of $46,000,000)
• Luminex U.S. Revenue (2024): $194,800,000 (representing approximately 40% of total global revenue)
• Current Royalty at 4.5%: approximately $8,766,000 per annum (4.5% × $194,800,000)
• Proposed Royalty at 6.0%: approximately $11,688,000 per annum (6.0% × $194,800,000)
• Incremental Annual Royalty Shift: approximately $2,922,000
E. Conclusion
Based on our analysis of the applicable U.S. and Swiss transfer pricing rules, the OECD Transfer Pricing Guidelines, the U.S.-Switzerland income tax treaty, and the findings of the Pendleton & Associates LLP Benchmark Study, we conclude that the proposed 6.0% royalty rate falls within the arm's-length range identified in the Benchmark Study (interquartile range of 4.0% to 8.5%, with a median of approximately 6.2%) and is defensible under both U.S. (IRC § 482 and the Treasury Regulations promulgated thereunder) and Swiss/OECD transfer pricing principles. The restructuring should be implemented in accordance with the documentation and procedural recommendations set forth in Sections VII and IX of this memorandum.
II. BACKGROUND
A. Transaction Overview
Ardent Capital Partners III LP, a Delaware limited partnership with its principal offices at 399 Park Avenue, 42nd Floor, New York, New York 10022 ("Ardent Fund III"), is the acquiring fund in this transaction. Ardent Fund III is a 2023 vintage private equity fund with total capital commitments of $12.5 billion, managed by Ardent Capital Management LLC. Theodore "Ted" Hargrove and Victoria Langford serve as Managing Partners of Ardent Capital Management LLC and are the principal deal team leads on this acquisition.
Ardent Fund III, through its acquisition vehicle, is acquiring Luminex Systems Holdings Inc. for aggregate merger consideration of $2,800,000,000 in an all-cash transaction structured as a reverse triangular merger under Delaware General Corporation Law. The transaction mechanics are as follows:
(a) Ardent Apex Holdings Inc., a Delaware corporation incorporated on March 5, 2025 (EIN: 93-2178435), was formed as the post-closing parent holding company (the "Parent").
(b) Ardent Apex Merger Sub Inc. ("Merger Sub"), a Delaware corporation incorporated on March 7, 2025 (EIN: 93-2178502), was formed as a wholly owned direct subsidiary of Apex Holdings for the sole purpose of effecting the merger.
(c) Pursuant to the Agreement and Plan of Merger dated March 24, 2025 (the "Merger Agreement"), Merger Sub will merge with and into Luminex Holdings (the "Merger"), with Luminex Holdings surviving the Merger as a wholly owned subsidiary of Apex Holdings.
(d) At the effective time of the Merger, each outstanding share of Luminex Holdings common stock (other than shares held by rollover participants, dissenting shares, and treasury shares) will be converted into the right to receive $20.00 per share in cash, representing an aggregate merger consideration of $2,800,000,000 based on 140,000,000 fully diluted shares outstanding.
The estimated Closing date is Q3 2025 (July through August 2025), subject to the satisfaction of customary closing conditions, including regulatory approvals. The Merger Agreement was duly executed on March 24, 2025.
B. Luminex Corporate Structure Relevant to Transfer Pricing
An understanding of the Luminex corporate structure is essential to the transfer pricing analysis. The principal entities are as follows:
Luminex Systems AG (Swiss Parent and IP Owner). Luminex AG is the ultimate operating parent of the Luminex group, organized as a Swiss Aktiengesellschaft under the laws of Switzerland, with its registered offices in the Canton of Glenrock Assurance at Bahnhofstrasse 71, 8001 Zürich (Commercial Register No. CHE-284.391.057). Luminex AG was founded in 2009 and serves as the legal and economic owner of the core Luminex One intellectual property portfolio. The current management team includes Dr. Stefan Kessler (Chief Executive Officer), Annelise Gruber (Chief Financial Officer), Dr. Markus Vogt (Chief Technology Officer), and Roland Merz (Chairman of the Board of Directors). Luminex AG employs approximately 4,200 individuals globally, with the majority of its engineering and product development personnel based in Zürich and Munich.
Luminex Systems Holdings Inc. (U.S. Intermediate Holding Company). Luminex Holdings is a Delaware corporation (EIN: 86-2547193) incorporated on June 14, 2021, as part of a corporate reorganization that established a mirrored share structure between Luminex AG and Luminex Holdings. Luminex Holdings serves as the U.S. intermediate holding company and is the direct parent of Luminex US. Following the Merger, Luminex Holdings will survive as a wholly owned subsidiary of Apex Holdings.
Luminex Systems Inc. (U.S. Operating Subsidiary). Luminex US is a Delaware corporation (EIN: 86-2547210) and the principal U.S. operating subsidiary of the Luminex group. Luminex US maintains its principal offices at 2100 Reston Gateway Drive, Suite 800, Reston, Virginia 20191, and employs approximately 1,650 individuals in the United States. Luminex US is responsible for the sales, marketing, customer success, professional services, and certain product development functions relating to the Luminex One platform in the North American market. For the fiscal year ended December 31, 2024, Luminex US generated net revenues of approximately $194,800,000, representing approximately 40% of the Luminex group's total global revenue.
Other Operating Subsidiaries. The Luminex group also maintains the following operating subsidiaries in other jurisdictions:
(a) Luminex Systems UK Ltd. — a private limited company organized under the laws of England and Wales (Company No. 12847362), with registered offices at 14 Broadwick Street, London W1F 8HN, United Kingdom, responsible for sales and operations in the United Kingdom and Nordics region.
(b) Luminex Systems GmbH — a German limited liability company (Gesellschaft mit beschränkter Haftung) registered in Munich (HRB 247891), with offices at Leopoldstrasse 120, 80802 Munich, Germany, responsible for sales and operations in the DACH region (excluding Switzerland) and serving as a secondary R&D center. Veltronix GmbH generated German revenues of approximately €67,000,000 in 2024.
(c) Luminex Systems Pte. Ltd. — a Singapore private limited company (UEN: 201924781K), with offices at 8 Marina Boulevard, #36-01, Singapore 018981, responsible for sales and operations in the Asia-Pacific region.
Key Markets by Revenue (2024). The Luminex group's revenue is distributed across the following principal geographic markets: DACH region (35%), North America (40%), United Kingdom and Nordics (15%), and Asia-Pacific (10%).
Product. The Luminex One platform is a cloud-based enterprise resource planning (ERP), procurement automation, and supply-chain analytics SaaS platform. The platform is sold predominantly on a subscription basis (accounting for $441,000,000 in ARR globally in 2024), with additional professional services revenue of $46,000,000 generated from implementation, customization, and consulting engagements.
C. Pre-Acquisition Ownership
Prior to the execution of the Merger Agreement, the equity ownership of Luminex Holdings (and, by extension, the economic interest in the Luminex group) was held as follows:
(a) Ridgeline Growth Equity Fund II LP: 52% of the outstanding equity interests. Ridgeline Growth Equity is a growth equity firm headquartered at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. Jonathan Ashford serves as Managing Partner.
(b) Management and employees: 28% of the outstanding equity interests (held through a combination of direct equity grants, stock options, and restricted stock units).
(c) Meridian Venture Partners IV LP: 20% of the outstanding equity interests. Meridian Venture Partners is a venture capital firm headquartered at 600 Montgomery Street, Suite 2800, San Francisco, California 94111. Claire Fujimoto serves as Managing Partner.
D. Post-Closing Ownership Structure
Following the Closing, the corporate structure will be reorganized as follows. Ardent Apex Holdings Inc. will serve as the ultimate parent holding company. Directly beneath Apex Holdings, Luminex Holdings will be the surviving corporation of the reverse triangular merger. Luminex Holdings will continue to hold its interests in Luminex AG and Luminex US, and Luminex AG will continue to hold its interests in Veltronix GmbH, Luminex UK Ltd., and Luminex Pte. Ltd. The organizational chart reflecting the post-closing structure is set forth in Exhibit B.
Certain members of the Luminex management team have agreed to participate in equity rollover transactions, pursuant to which they will contribute a portion of their merger proceeds into equity of Apex Holdings. The aggregate management rollover equity is $405,020,000, allocated as follows:
In addition, the following equity co-investors will invest alongside Ardent Fund III:
(a) Northvale Sovereign Holdings Ltd.: $200,000,000 equity co-investment.
(b) Summit Ridge Capital Partners LP: $100,000,000 equity co-investment.
E. Existing Intercompany IP License Arrangement
The intercompany intellectual property license arrangement between Luminex AG and Luminex US was established in connection with the 2021 corporate reorganization. The key terms of the Existing License Agreement are as follows:
IP Ownership. Luminex AG is the legal and economic owner of the core Luminex One intellectual property, which encompasses an extensive portfolio of patents, copyrights, trade secrets, proprietary algorithms, and trademarks. The IP was originally developed by Luminex AG's engineering teams in Zürich, with supplemental development contributions from the Munich office. Luminex AG has maintained continuous ownership, registration, and protection of the IP since its inception.
License Grant. Under the Existing License Agreement, Luminex AG grants to Luminex US an exclusive (within the territory of the United States) license to use, reproduce, display, and sublicense the Luminex One platform IP in connection with the marketing, sale, and delivery of the Luminex One platform to customers in the United States.
Royalty Rate. Luminex US pays Luminex AG a royalty equal to 4.5% of Luminex US net revenues (defined as U.S.-source revenue net of returns and allowances). For the fiscal year ended December 31, 2024, the royalty payment from Luminex US to Luminex AG was approximately $8,766,000 (4.5% × $194,800,000).
R&D Functions and Cost-Sharing. Luminex AG performs the substantial majority of research and development functions related to the Luminex One platform from its offices in Zürich and Munich. Luminex US performs certain limited product development functions relating to U.S.-market-specific feature development and localization. IP development costs are primarily borne by Luminex AG, with Luminex US making certain cost-sharing contributions for U.S.-market-specific feature development under a separate cost contribution arrangement. The cost-sharing contributions are not the subject of this memorandum but should be reviewed for consistency with the revised royalty rate.
Excerpts of the key commercial terms of the Existing License Agreement are attached as Exhibit F for reference.
III. APPLICABLE LEGAL AND REGULATORY FRAMEWORK
A. U.S. Transfer Pricing Rules (IRC § 482 and Treasury Regulations)
The foundational U.S. transfer pricing provision is Section 482 of the Internal Revenue Code, which grants the Secretary of the Treasury (and by delegation, the Internal Revenue Service) the authority to "distribute, apportion, or allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests" in order "to prevent evasion of taxes or clearly to reflect the income" of such organizations. The overarching principle underlying Section 482 is the arm's-length standard — that is, controlled transactions should produce results consistent with results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.
The Treasury Regulations under Section 482, specifically Treas. Reg. §§ 1.482-1 through 1.482-9, prescribe detailed methods for determining arm's-length pricing across different categories of intercompany transactions, including transfers of tangible property (Treas. Reg. § 1.482-3), transfers of intangible property (Treas. Reg. § 1.482-4), controlled services transactions (Treas. Reg. § 1.482-9), and cost-sharing arrangements (Treas. Reg. § 1.482-7).
For the intercompany licensing of intangible property — which is the transaction at issue here — Treas. Reg. § 1.482-4 prescribes several acceptable transfer pricing methods, including:
(a) Comparable Uncontrolled Transaction (CUT) Method (Treas. Reg. § 1.482-4(c)): The CUT method evaluates whether the amount charged in a controlled transaction is arm's length by reference to the amount charged in a comparable uncontrolled transaction. This is the preferred method when reliable comparable uncontrolled transactions can be identified.
(b) Comparable Profits Method (CPM) (Treas. Reg. § 1.482-5): The CPM evaluates whether the amount charged in a controlled transaction is arm's length by reference to objective measures of profitability (profit level indicators, or PLIs) derived from uncontrolled taxpayers that engage in comparable transactions under comparable circumstances. This method is often used as a corroborative method when CUT data are available.
(c) Profit Split Method (Treas. Reg. § 1.482-6): The profit split method evaluates the relative contributions of each party to the combined profit of the controlled transaction, allocating income based on the relative value of each party's contributions.
(d) Unspecified Methods (Treas. Reg. § 1.482-4(d)): Other methods may be used if they provide a more reliable measure of an arm's-length result than the specified methods.
Of particular significance to the analysis of intangible property transactions is the "commensurate-with-income" standard codified in the second sentence of IRC § 482, which provides that "[i]n the case of any transfer (or license) of intangible property . . . the income with respect to such transfer or license shall be commensurate with the income attributable to the intangible." This standard was enacted by the Tax Reform Act of 1986 and imposes an ongoing obligation to ensure that the royalty rate remains appropriate as the income attributable to the licensed intangible evolves over time. The commensurate-with-income standard may require periodic adjustments to the royalty rate and supports the establishment of an annual review protocol, as recommended in Section IX below.
The penalty provisions under IRC § 6662(e) and (h) are also directly relevant to this analysis. Section 6662(e) imposes a 20% penalty on any underpayment attributable to a "substantial valuation misstatement" in connection with a transfer pricing adjustment (generally, a Section 482 adjustment exceeding the lesser of $5 million or 10% of the taxpayer's gross receipts). Section 6662(h) doubles the penalty to 40% for a "gross valuation misstatement" (generally, an adjustment exceeding the lesser of $20 million or 20% of the taxpayer's gross receipts). However, Treas. Reg. § 1.6662-6(d) provides that a taxpayer may avoid these penalties by maintaining "contemporaneous documentation" establishing that it selected and applied the most reliable transfer pricing method in a reasonable manner — a defense that underscores the critical importance of the documentation recommendations set forth in Section VII.B of this memorandum.
B. Swiss Transfer Pricing Rules
Switzerland does not have a specific statutory transfer pricing regime comparable to IRC § 482 and its implementing regulations. However, Switzerland follows the arm's-length principle consistent with the OECD Transfer Pricing Guidelines, and the Swiss Federal Tax Administration (FTA) has consistently applied this principle in its administrative practice and in published circulars.
Under Swiss tax law, intercompany transactions between related parties must reflect terms and conditions that unrelated parties would have agreed to under comparable circumstances. Deviations from arm's-length pricing may result in adjustments by the Swiss tax authorities — either an upward adjustment to income (where a Swiss entity has undercharged a related party) or a disallowance of deductions (where a Swiss entity has overpaid a related party). In the present case, the proposed restructuring increases the royalty income received by Luminex AG, which is directionally favorable from a Swiss tax perspective and is unlikely to be challenged by the Swiss FTA.
Swiss tax practice also provides for the issuance of advance tax rulings and, in appropriate cases, the negotiation of advance pricing agreements (APAs). The Swiss FTA has participated in bilateral APAs with the United States and other jurisdictions, and this avenue remains available if additional certainty is desired following the initial post-closing implementation period.
The cantonal tax regime is also relevant. Luminex AG is domiciled in the Canton of Glenrock Assurance, which applies a combined federal and cantonal corporate income tax rate of approximately 14% to 15% for qualifying companies. This rate differential — significantly below the U.S. federal corporate income tax rate of 21% — is the fundamental driver of the global tax benefit from the royalty restructuring, as each dollar of additional royalty deduction reduces U.S. tax at 21% while generating incremental Swiss income taxed at approximately 14% to 15%.
C. OECD Transfer Pricing Guidelines (2022 Edition)
The OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (the "OECD Guidelines"), most recently updated in January 2022, provide the internationally accepted framework for the application of the arm's-length principle. Both the United States and Switzerland are members of the OECD and broadly adhere to the OECD Guidelines, though the United States has certain statutory and regulatory provisions (such as the commensurate-with-income standard) that go beyond or supplement the OECD framework.
The following chapters of the OECD Guidelines are particularly relevant to the analysis:
Chapters I through III address the foundational arm's-length principle, comparability analysis, and the recognized transfer pricing methods. The guidelines emphasize that the selection of the most appropriate transfer pricing method must be based on a thorough functional analysis of the controlled transaction, including the functions performed, assets employed, and risks assumed by each party.
Chapter VI provides special considerations for transactions involving intangible property and is of central importance to the present analysis. Chapter VI introduced the DEMPE framework, which requires an analysis of which entity within a multinational group performs (or exercises control over and bears the financial risks associated with) the functions of Development, Enhancement, Maintenance, Protection, and Exploitation of the intangible property. Under the DEMPE framework, the entity that performs (and bears the cost and risk of) the economically significant DEMPE functions is entitled to the residual income from the intangible, regardless of legal ownership alone.
As applied to the Luminex group, the DEMPE analysis supports the proposition that Luminex AG is entitled to the predominant share of the income attributable to the Luminex One IP, given that Luminex AG performs the Development, Enhancement, Maintenance, and Protection functions, while Luminex US's role is principally limited to Exploitation (i.e., marketing and distribution) within the U.S. market, with limited Enhancement contributions. This analysis is set forth in greater detail in Section IV below.
Chapter VI also provides guidance on hard-to-value intangibles, which may be relevant in the context of the Section 338(h)(10) analysis and the purchase price allocation for the Luminex One IP portfolio.
D. U.S.-Switzerland Income Tax Treaty
The Convention Between the United States of America and the Swiss Confederation for the Avoidance of Double Taxation with Respect to Taxes on Income, signed on October 2, 1996, as amended by the 2009 Protocol (the "Treaty"), governs the allocation of taxing rights between the United States and Switzerland with respect to cross-border income, including royalty payments.
Article 12 (Royalties). Article 12 of the Treaty provides that royalties arising in a Contracting State (here, the United States, as the source of the royalty payment) and paid to a resident of the other Contracting State (here, Switzerland, as the residence of Luminex AG) may be taxed in the Contracting State in which they arise, but the tax so charged shall not exceed a specified percentage of the gross amount of the royalties. Under the Treaty as amended by the 2009 Protocol, the rate of withholding tax on royalties is generally 0% where the beneficial owner is a resident of the other Contracting State, provided that the limitation-on-benefits (LOB) requirements of Article 22 are satisfied.
Article 7 (Business Profits). Article 7 governs the taxation of business profits attributable to a permanent establishment in the other Contracting State. To the extent that the intercompany royalty arrangement does not give rise to a permanent establishment of Luminex AG in the United States (and based on our review, it does not), Article 7 does not impose additional U.S. taxing rights beyond the royalty provision in Article 12.
Article 22 (Limitation on Benefits). Article 22 contains the LOB provisions that must be satisfied in order for Luminex AG to claim the reduced withholding tax rates under the Treaty. As discussed in Section VII.D below, Luminex AG's post-closing ownership by Apex Holdings (a U.S. corporation) should satisfy the ownership and base erosion tests under the LOB article, though this analysis must be confirmed at Closing.
Swiss Withholding Tax. Swiss domestic withholding tax (the "anticipatory tax" or Verrechnungssteuer) is imposed at a statutory rate of 35% on certain categories of passive income, principally dividends. Importantly, royalty payments between affiliated companies are generally not subject to Swiss anticipatory tax — the 35% rate applies to dividends, interest on certain instruments, and lottery winnings, but not to royalties per se. Accordingly, the incremental royalty payments from Luminex US to Luminex AG should not trigger Swiss anticipatory tax. A separate memorandum prepared by the undersigned addresses the Swiss anticipatory tax on deemed dividends and the treaty rate reduction to 5% in the context of other aspects of the post-closing capital structure.
E. Other Jurisdictional Considerations
The restructuring of the Luminex AG / Luminex US intercompany licensing arrangement does not occur in isolation. To the extent that the underlying rationale for adjusting the royalty rate (i.e., alignment with arm's-length benchmarks) applies to the intercompany arrangements between Luminex AG and its other operating subsidiaries, a coordinated review of those arrangements is warranted. The principal jurisdictional considerations are as follows:
Germany (Luminex Systems GmbH). German transfer pricing rules are codified in the Aussensteuergesetz (AStG), particularly Section 1 of the AStG, as well as in the general income tax provisions of the Einkommensteuergesetz (EStG) and Körperschaftsteuergesetz (KStG). Germany has among the most rigorous transfer pricing enforcement regimes in Europe, and the German tax authorities (Betriebsprüfung) routinely examine intercompany transactions during tax audits. We are coordinating with Dr. Katarina Wendt at Wendt Schäfer Rechtsanwälte PartG mbB (Maximilianstrasse 35, 80539 Munich) regarding the implications of the proposed restructuring for Veltronix GmbH and the German transfer pricing documentation requirements. Given that Veltronix GmbH generated approximately €67,000,000 in German revenues in 2024, any adjustment to the royalty rate between Luminex AG and Veltronix GmbH could have material tax consequences in Germany.
United Kingdom (Luminex Systems UK Ltd.). The UK transfer pricing rules are set forth in Part 4 of the Taxation (International and Other Provisions) Act 2010 ("TIOPA 2010"). TIOPA 2010 requires that transactions between connected persons be priced at arm's length and imposes documentation requirements. Luminex UK Ltd. (Company No. 12847362) should be subject to a parallel review of its intercompany licensing terms with Luminex AG to ensure consistency with the revised global transfer pricing policy.
Singapore (Luminex Systems Pte. Ltd.). Singapore's transfer pricing guidelines are set forth in the Inland Revenue Authority of Singapore (IRAS) e-Tax Guide on Transfer Pricing Guidelines, most recently updated in 2024. We are coordinating with Kelvin Tan at Tan Liang & Associates LLP (80 Raffles Place, #32-01, Singapore 048624) regarding the implications for Luminex Pte. Ltd. (UEN: 201924781K) and any necessary adjustments to the Singapore intercompany arrangements.
The overarching objective is to ensure global consistency of the Luminex group's transfer pricing policy across all jurisdictions, such that each local entity's intercompany charges are supportable on an arm's-length basis and are documented in accordance with local requirements.
IV. FUNCTIONAL ANALYSIS
A comprehensive functional analysis is the foundation of any transfer pricing determination. Consistent with the requirements of Treas. Reg. § 1.482-1(d)(3) and the OECD Transfer Pricing Guidelines (Chapters I through III and Chapter VI), this section identifies and evaluates the functions performed, assets employed, and risks assumed by each of Luminex AG and Luminex US in connection with the intercompany IP licensing arrangement.
A. Functions Performed by Luminex Systems AG (IP Licensor)
Luminex AG, as the legal and economic owner of the Luminex One intellectual property, performs the following principal functions:
Research and Development / Core Product Development. Luminex AG is responsible for the development and ongoing enhancement of the Luminex One platform. The substantial majority of the company's engineering headcount — comprising software engineers, data scientists, product managers, and quality assurance professionals — is based in Zürich and Munich. Luminex AG's R&D expenditures have consistently represented approximately 22% to 25% of total group revenue, a level consistent with industry benchmarks for enterprise SaaS companies in the growth phase.
intellectual Property Ownership, Management, Protection, and Maintenance. Luminex AG holds legal title to the core IP portfolio, which includes registered patents (in multiple jurisdictions), copyrights in the source code and documentation, trade secrets relating to proprietary algorithms and machine learning models, and registered trademarks (including the "Luminex" and "Luminex One" marks). Luminex AG manages the global IP portfolio, including patent prosecution and maintenance, trademark registration and renewal, enforcement actions against infringers, and the implementation of trade secret protection protocols (including employee confidentiality agreements, access controls, and information security measures).
Global Product Strategy and Roadmap. Luminex AG's executive team, led by Dr. Stefan Kessler (CEO) and Dr. Markus Vogt (CTO), is responsible for defining the global product strategy and roadmap for the Luminex One platform. Strategic product decisions — including the prioritization of new features, the selection of technology architecture, and the allocation of R&D resources — are made at the Luminex AG level.
Certain Global Marketing Functions. Luminex AG performs certain centralized marketing functions, including brand management, global marketing strategy, and the development of marketing materials and thought leadership content for use across the group.
DEMPE Analysis. Applying the Chapter VI DEMPE framework, Luminex AG performs the Development functions (it is the primary developer of the Luminex One platform), the Enhancement functions (it is responsible for ongoing product improvements and new feature development), the Maintenance functions (it maintains the IP portfolio, including patent prosecution and trade secret protection), and the Protection functions (it enforces IP rights against third-party infringers and manages the global trademark portfolio). Luminex AG shares the Exploitation function with local operating entities, including Luminex US, which perform the marketing, sales, and distribution activities necessary to commercialize the IP in their respective territories.
B. Functions Performed by Luminex Systems Inc. (IP Licensee)
Luminex US, as the licensee of the Luminex One platform IP for the U.S. market, performs the following principal functions:
Sales and Distribution. Luminex US is responsible for the marketing, sale, and distribution of the Luminex One platform to enterprise customers in the United States. The U.S. sales organization includes field sales representatives, account executives, sales engineers, and sales management, organized by vertical market and geographic territory. In 2024, Luminex US generated net revenues of approximately $194,800,000 from U.S. customers.
Customer Success, Support, and Professional Services. Luminex US maintains a substantial customer success organization responsible for onboarding, training, and ongoing support of U.S. customers. Luminex US also provides professional services — including implementation, customization, integration, and consulting — to U.S. customers. Total global professional services revenue was $46,000,000 in 2024, with the U.S. portion being proportional to the U.S. share of total revenue.
U.S.-Market-Specific Product Localization and Feature Development. Luminex US performs certain product development functions that are specific to the requirements of the U.S. market, including regulatory compliance features (e.g., features relating to FAR/DFARS compliance for U.S. government contracts), integrations with U.S.-specific third-party platforms, and localization of the user interface for U.S. English and U.S. accounting standards. These contributions are limited in scope relative to the core platform development performed by Luminex AG.
Marketing and Demand Generation. Luminex US conducts U.S.-focused marketing and demand generation activities, including participation in industry conferences and trade shows, digital marketing campaigns, content marketing, webinars, and analyst relations within the North American market.
Workforce. Luminex US employs approximately 1,650 individuals in the United States across its sales, marketing, customer success, professional services, product development, and general and administrative functions.
DEMPE Analysis. Applying the DEMPE framework to Luminex US, this entity primarily performs Exploitation functions — that is, the activities necessary to commercialize the Luminex One platform within the U.S. market through sales, marketing, and customer support. Luminex US makes limited Enhancement contributions through its U.S.-market-specific product development activities, but these contributions are ancillary to the core Development and Enhancement functions performed by Luminex AG. Luminex US does not perform Maintenance or Protection functions with respect to the IP portfolio.
C. Assets Employed
The assets employed by each entity in connection with the intercompany licensing arrangement are as follows:
Luminex AG: Luminex AG's principal assets include the core IP portfolio (patents, copyrights, trade secrets, proprietary algorithms, and machine learning models), the Luminex and Luminex One brand and trademarks, non-U.S. customer relationships, R&D infrastructure (including laboratory and office facilities in Zürich and Munich, development tools, testing environments, and cloud infrastructure for R&D purposes), and the assembled technical workforce.
Luminex US: Luminex US's principal assets include U.S. customer relationships (including long-term enterprise subscriptions and a significant book of recurring revenue), the assembled U.S. workforce, local marketing assets and customer data, and limited derivative intellectual property created from U.S.-specific product customization work. Luminex US also maintains office facilities in Reston, Virginia, and other U.S. locations.
Capital Employed. Luminex AG bears the predominant R&D investment risk, having funded the development of the Luminex One platform since its inception in 2009 and continuing to invest approximately 22% to 25% of group revenue annually in R&D. Luminex US bears the costs of sales, marketing, and customer acquisition in the U.S. market, which represent the primary operational expenditures at the U.S. entity level.
D. Risks Assumed
The allocation of economically significant risks between the parties is a critical element of the functional analysis:
Luminex AG: Luminex AG assumes the principal risks associated with the development and ownership of the IP, including (i) technology development risk (the risk that R&D investments may not yield commercially viable products or features), (ii) IP obsolescence risk (the risk that the Luminex One technology may become obsolete due to competitive innovation or technological disruption), (iii) global competitive risk (the risk that competitors may capture market share through superior products, pricing, or go-to-market strategies), and (iv) regulatory risk in non-U.S. markets (the risk that changes in regulations may affect the saleability or value of the platform outside the United States).
Luminex US: Luminex US assumes the principal risks associated with the commercialization of the IP in the U.S. market, including (i) U.S. market risk (the risk that demand for the Luminex One platform in the United States may decline due to macroeconomic conditions, competitive pressures, or changes in customer preferences), (ii) U.S. regulatory and compliance risk (including risks associated with U.S. government contracts, as further described in the CFIUS filing — Luminex US maintains contracts with the U.S. Department of Defense (logistics applications), the U.S. Department of Energy (procurement), and holds a GSA enterprise license), (iii) customer concentration risk (including the concentration of revenue among the largest U.S. enterprise accounts), and (iv) credit and collection risk on U.S. accounts receivable.
A summary of the functional analysis applying the DEMPE framework is set forth in Exhibit C.
V. PENDLETON & ASSOCIATES LLP BENCHMARK STUDY
A. Overview of Study
The transfer pricing benchmark study (the "Benchmark Study") was conducted by Pendleton & Associates LLP, a transfer pricing advisory firm with offices at 30 Rockefeller Plaza, Suite 2600, New York, New York 10112. The Benchmark Study was led by Richard Chow, the lead engagement partner. The scope of the Benchmark Study was to determine the arm's-length royalty rate for the intragroup licensing of the Luminex One platform IP between Luminex AG (as licensor) and Luminex US (as licensee), taking into account the specific characteristics of the transaction, the functions performed and risks assumed by each party, and the economic circumstances of the arrangement.
Pendleton & Associates LLP applied two recognized transfer pricing methods in conducting the Benchmark Study: (i) the Comparable Uncontrolled Transaction (CUT) method, as the primary method, and (ii) the Comparable Profits Method (CPM), also referred to as the Transactional Net Margin Method (TNMM) under the OECD Guidelines, as a corroborative method. The selection of the CUT method as the primary method is consistent with the priority of methods set forth in Treas. Reg. § 1.482-4, which recognizes the CUT method as the preferred method when sufficiently reliable comparable uncontrolled transactions can be identified.
B. Comparable Uncontrolled Transaction (CUT) Analysis
The CUT analysis involved a systematic search for third-party intellectual property licensing agreements in the enterprise software and SaaS industry involving licenses of intangible property comparable to the Luminex One platform IP. The search was conducted using recognized transfer pricing databases, including Vireo Health IT and Sundial Health IT, supplemented by publicly available SEC filings, license agreement disclosures, and industry databases.
Selection Criteria. The search for comparable uncontrolled transactions was conducted using the following selection criteria:
(a) Industry: Enterprise software, SaaS, ERP, procurement software, and supply-chain management software.
(b) Geographic Comparability: Licensing arrangements involving a U.S. licensee and a European or Swiss licensor, or comparable cross-border arrangements between developed-market jurisdictions.
(c) Functional Comparability: Full platform technology licenses (as opposed to limited-function or single-module licenses), where the licensor is the primary IP developer and the licensee performs distribution, marketing, and support functions.
(d) Contractual Terms: Revenue-based royalty arrangements (as opposed to lump-sum or milestone-based payments), with comparability adjustments made for differences in license exclusivity, territory scope, and ancillary service obligations.
Results. The CUT analysis identified a set of comparable uncontrolled transactions from which Pendleton & Associates LLP derived the following arm's-length royalty rate range:
• Interquartile Range: 4.0% to 8.5% of net revenues
• Median: approximately 6.2% of net revenues
The current 4.5% royalty rate, while falling within the lower portion of the interquartile range, is below the interquartile median and does not fully reflect the value of the comprehensive IP license granted by Luminex AG to Luminex US, particularly in light of Luminex AG's significant ongoing R&D investment and the DEMPE functions it performs. The proposed 6.0% royalty rate falls within the arm's-length range and near the median, representing a more accurate reflection of the arm's-length consideration for the licensed IP.
A summary of the comparable royalty rate data is set forth in Exhibit A.
C. Comparable Profits Method / Transactional Net Margin Method (Corroborative)
As a corroborative method, Pendleton & Associates LLP applied the Comparable Profits Method (CPM) under U.S. regulations (or the TNMM under OECD terminology) to confirm that the proposed royalty rate produces an arm's-length result for Luminex US.
Tested Party. Luminex US was selected as the tested party, as it is the less complex entity in the controlled transaction, performing principally distribution, marketing, customer success, and limited product development functions. Luminex AG, as the IP owner and primary developer, performs the more complex and unique functions and is therefore less suitable as the tested party.
Profit Level Indicator (PLI). The PLIs examined included the operating margin (operating income divided by net revenues) and the Berry ratio (gross profit divided by operating expenses). The operating margin was selected as the primary PLI based on its reliability and the availability of comparable data.
Comparable Company Set. Pendleton & Associates LLP conducted a search for comparable U.S. companies engaged in the distribution and marketing of licensed enterprise software and SaaS platforms under arrangements similar to Luminex US's functional profile. The search yielded a set of comparable companies with the following operating margin characteristics:
• Interquartile Range: 8% to 18% operating margin
• Median: approximately 13% operating margin
Application to Luminex US. Luminex US's 2024 operating margin, computed after deduction of the current 4.5% royalty, falls within the upper portion of the interquartile range for comparable distributors. Luminex US's projected operating margin after deduction of the proposed 6.0% royalty also falls within the interquartile range, confirming that the higher royalty rate does not compress Luminex US's profitability below the arm's-length range for comparable distributors.
Conclusion. The CPM/TNMM analysis corroborates the CUT analysis conclusion that the proposed 6.0% royalty rate is arm's length. Luminex US retains a level of profitability consistent with its functional profile and risk assumption, while Luminex AG receives compensation commensurate with its IP ownership, DEMPE functions, and R&D investment.
D. Conclusion of Benchmark Study
Based on the foregoing analyses, the Benchmark Study concludes as follows:
(a) The proposed 6.0% royalty rate is within the arm's-length interquartile range of 4.0% to 8.5% of net revenues and is near the median of approximately 6.2%.
(b) Both the CUT method (as the primary method) and the CPM/TNMM (as the corroborative method) support the proposed 6.0% rate as an arm's-length charge for the license of the Luminex One platform IP from Luminex AG to Luminex US.
(c) Pendleton & Associates LLP has confirmed their willingness to prepare a formal, comprehensive transfer pricing report documenting the analysis and to defend the position in the event of an examination or audit by the IRS, the Swiss FTA, or any other relevant tax authority.
VI. FINANCIAL IMPACT ANALYSIS
A. Impact on Luminex US (Licensee)
The financial impact of the proposed restructuring on Luminex US is summarized as follows, based on 2024 revenue levels:
The incremental annual royalty deduction for Luminex US of approximately $2,922,000 generates an incremental U.S. federal income tax benefit of approximately $613,620 per year at the current 21% corporate income tax rate.
In addition to the federal tax benefit, the incremental royalty deduction will generate state and local tax savings in those jurisdictions where Luminex US has nexus and where the royalty payment reduces apportioned taxable income. Luminex US has nexus in Virginia (its principal place of business), California, and several other states in which it maintains sales offices, employees, or economic nexus arising from customer revenue. The state and local tax benefit is dependent on each state's apportionment methodology, conformity with federal rules regarding intercompany royalty deductions (including addback statutes in certain states), and applicable tax rates. These considerations are addressed in a separate State & Local Tax Considerations Memorandum and are not quantified in detail here.
With respect to the impact on Luminex US's operating margin, the incremental royalty charge of approximately $2,922,000 on a revenue base of $194,800,000 represents a reduction in operating margin of approximately 1.5 percentage points. Based on the CPM/TNMM analysis, Luminex US's post-restructuring operating margin remains within the arm's-length interquartile range for comparable U.S. distributors of licensed enterprise software, confirming that the restructuring does not impair Luminex US's economic position below the level that an unrelated distributor would accept.
B. Impact on Luminex AG (Licensor)
The incremental royalty income received by Luminex AG as a result of the restructuring is approximately $2,922,000 per year (based on 2024 U.S. revenue levels). This incremental income is subject to Swiss federal and cantonal (Glenrock Assurance) corporate income tax at an estimated effective combined rate of approximately 14% to 15%.
The net global tax benefit from the restructuring is the difference between the U.S. federal tax benefit of the incremental deduction and the Swiss tax cost on the incremental income:
When state and local tax savings are included, the aggregate annual tax benefit is expected to be somewhat higher. Importantly, the absolute dollar benefit scales proportionally with the growth of Luminex US revenues. The Luminex group's U.S. revenue has grown at a compound annual growth rate of approximately 20% to 25% over the past three years, and if this trajectory continues (or even moderates), the incremental royalty shift — and the associated tax benefit — will increase meaningfully in absolute terms over the medium to long term.
A sensitivity analysis illustrating the financial impact at various royalty rates (4.5%, 5.0%, 5.5%, 6.0%, 6.5%, and 7.0%) across multiple revenue growth scenarios is set forth in Exhibit D.
C. Interaction with Section 338(h)(10) Analysis
The transfer pricing restructuring should be considered in conjunction with the potential Section 338(h)(10) election that is the subject of a separate Tax Structure Memorandum prepared by Calderwood & Harkness LLP. If a Section 338(h)(10) election is made in connection with the acquisition, the election would result in a deemed asset sale by Luminex Holdings and a corresponding step-up in the tax basis of Luminex Holdings' assets (including the equity interests in Luminex US and, indirectly, the intangible assets associated with the Luminex One platform IP in the U.S. context) to fair market value as of the Closing date.
The estimated step-up in amortizable intangible assets under the Section 338(h)(10) election is approximately $620,000,000, generating estimated annual federal tax amortization deductions of approximately $41,333,333 (assuming a 15-year amortization period under IRC § 197) and corresponding annual federal tax savings of approximately $8,680,000 (at the 21% corporate rate). The present value of the aggregate tax savings from the step-up, discounted at 8% over 15 years, is approximately $195,000,000.
The transfer pricing restructuring is independent of but complementary to the Section 338(h)(10) election. The royalty restructuring addresses the ongoing intercompany pricing of the IP license between Luminex AG and Luminex US, while the Section 338(h)(10) election addresses the one-time purchase-price step-up at the time of acquisition. However, coordination between the two analyses is required to ensure consistency: the fair market value allocation of the purchase price to intangible assets for Section 338(h)(10) purposes must be consistent with the arm's-length royalty rate used for ongoing transfer pricing. A royalty rate that is supported by the arm's-length standard, when combined with projected revenue streams and an appropriate discount rate, should yield an implied IP valuation that is consistent with the intangible asset values derived in the purchase price allocation.
D. Interaction with Swiss Withholding Tax
As noted in Section III.D above, royalty payments from Luminex US to Luminex AG are not subject to Swiss anticipatory tax (the 35% statutory rate applies to dividends, not to royalties). Accordingly, the incremental royalty payments resulting from the restructuring do not trigger any additional Swiss withholding tax liability.
With respect to U.S. withholding tax, royalty payments from a U.S. payor to a Swiss resident are generally subject to 30% U.S. withholding tax under IRC §§ 1441 and 1442. However, under Article 12 of the U.S.-Switzerland Treaty, the withholding rate is reduced to 0% for royalties paid to a qualifying resident of Switzerland, provided that the LOB requirements of Article 22 are satisfied. As discussed in Section VII.D below, Luminex AG is expected to qualify for the 0% treaty rate following the Closing.
A detailed analysis of the Swiss withholding tax implications, including the 35% anticipatory tax on deemed dividends in the context of the broader post-closing capital structure, is set forth in a separate Swiss Withholding Tax Analysis Memorandum prepared by the undersigned.
VII. IMPLEMENTATION CONSIDERATIONS
A. Timing
The restructuring of the intercompany royalty rate should be implemented post-Closing of the reverse triangular merger. The amended intercompany license agreement (or a new intercompany license agreement replacing the Existing License Agreement) should become effective as of the Closing date or the first day of the post-closing fiscal period (whichever is administratively preferable and consistent with the tax positions of the parties).
The rationale for post-closing implementation is twofold:
(a) Control: Following the Closing, Ardent Apex Holdings Inc. will have full authority over both Luminex AG and Luminex US, enabling the parent company to implement the restructuring without the consent of the pre-closing sellers or the Luminex board acting in its pre-closing capacity.
(b) Merger Agreement Covenants: Under the interim operating covenants of the Merger Agreement (Section 5.01), Luminex Holdings has agreed to operate the business in the ordinary course between signing and Closing and to refrain from entering into, amending, or terminating any material contract (defined, in relevant part, as any contract involving annual payments or commitments in excess of $2,000,000) outside the ordinary course of business without the prior written consent of Ardent. The proposed restructuring, which involves an incremental annual royalty shift of approximately $2,922,000, exceeds the $2,000,000 materiality threshold and constitutes a transaction outside the ordinary course. Implementing the restructuring prior to Closing would therefore require Ardent's consent under the Merger Agreement and could raise issues with the pre-closing sellers regarding the allocation of economic benefits. Post-closing implementation avoids these complications entirely.
We recommend that the new or amended intercompany license agreement be substantially drafted and agreed in principle during the pre-closing period, so that it is ready for execution promptly upon Closing.
B. Documentation Requirements
The following documentation should be prepared and maintained in connection with the restructuring:
Amended Intercompany IP License Agreement. A new or amended intercompany IP license agreement between Luminex AG and Luminex US, reflecting the 6.0% royalty rate and updated commercial terms. Calderwood & Harkness will prepare the initial draft of the agreement, with input from Breitfeld Hess & Partner AG (Dr. Lukas Breitfeld, Talstrasse 62, 8001 Zürich) for Swiss law aspects, including compliance with Swiss corporate and tax law requirements. The agreement should include provisions addressing the definition of the royalty base (net revenues), payment timing and currency, the scope of the license grant, representations regarding IP ownership, dispute resolution, and term and termination.
U.S. Contemporaneous Transfer Pricing Documentation. Pendleton & Associates LLP will prepare contemporaneous transfer pricing documentation compliant with the requirements of Treas. Reg. § 1.6662-6(d), which provides for a penalty safe harbor where the taxpayer maintains documentation establishing that it selected and applied the "best method" in determining its transfer prices. The documentation will include a detailed description of the controlled transaction, a functional analysis, the selection and application of the CUT and CPM methods, the identification and analysis of comparable transactions and companies, and the conclusion that the 6.0% royalty rate is within the arm's-length range. This documentation should be prepared within 60 days of Closing and maintained on a rolling basis to ensure continued compliance with the commensurate-with-income standard.
Swiss Transfer Pricing Documentation. Parallel transfer pricing documentation should be prepared for Swiss compliance purposes, consistent with the OECD Transfer Pricing Guidelines and Swiss FTA expectations. Breitfeld Hess & Partner AG will take the lead on the Swiss documentation, in coordination with Pendleton & Associates LLP to ensure global consistency.
Board Resolutions. The boards of directors (or equivalent governing bodies) of both Luminex AG and Luminex US should adopt resolutions approving the amended intercompany licensing terms. The resolutions should recite the business rationale for the adjustment (i.e., alignment with arm's-length benchmarks), reference the Benchmark Study, and authorize the appropriate officers to execute the amended agreement. The board resolutions serve both a corporate governance function and a transfer pricing documentation function, providing contemporaneous evidence of the arm's-length intent of the parties.
Advance Pricing Agreement (APA). We have considered whether a unilateral APA (filed with the IRS) or a bilateral APA (negotiated between the IRS and the Swiss FTA) should be pursued to obtain certainty regarding the arm's-length nature of the 6.0% royalty rate. An APA provides prospective certainty for a specified term (typically five years) and can also cover rollback years. However, the APA process is time-consuming (typically 24 to 48 months for a bilateral APA), resource-intensive, and requires disclosure of sensitive financial and operational information to the relevant tax authorities. Our recommendation is to defer pursuit of an APA pending Closing and an initial post-closing operational period of 12 to 18 months, during which time the restructured arrangement will be in effect and audit risk can be monitored. If the IRS or Swiss FTA signals heightened interest in the intercompany arrangement, the APA process can be initiated at that time.
C. Impact on Other Intercompany Arrangements
As noted in Section III.E above, the rationale for adjusting the Luminex AG / Luminex US royalty rate may apply equally to the intercompany licensing arrangements between Luminex AG and its other operating subsidiaries. A review of these arrangements should be conducted in parallel with the implementation of the U.S. restructuring to ensure global consistency.
Luminex Systems GmbH (Germany). Veltronix GmbH generated approximately €67,000,000 in German revenues in 2024. The current intercompany royalty rate between Luminex AG and Veltronix GmbH should be reviewed to determine whether a corresponding adjustment is warranted. Coordination with Dr. Katarina Wendt at Wendt Schäfer Rechtsanwälte PartG mbB is essential, given Germany's rigorous transfer pricing enforcement environment and the specific requirements of the Aussensteuergesetz (AStG). German transfer pricing documentation requirements (Gewinnabgrenzungsaufzeichnungsverordnung, or GAufzV) should also be addressed.
Luminex Systems UK Ltd. (United Kingdom). The intercompany licensing terms between Luminex AG and Luminex UK Ltd. should be reviewed under TIOPA 2010, Part 4, to ensure compliance with UK arm's-length requirements. The UK's diverted profits tax (at 25%) may also be relevant if the intercompany arrangement is perceived as diverting profits from the UK.
Luminex Systems Pte. Ltd. (Singapore). The intercompany terms between Luminex AG and Luminex Pte. Ltd. should be reviewed in light of the IRAS Transfer Pricing Guidelines. Coordination with Kelvin Tan at Tan Liang & Associates LLP is recommended, particularly given Singapore's transfer pricing documentation and contemporaneous reporting requirements.
The overarching principle guiding the global review is that the transfer pricing policy should be consistent across jurisdictions, reflecting a unified methodology and a coherent allocation of income to the entities that perform the economically significant DEMPE functions.
D. U.S. Withh